Ups Plans To Invest $48m In Temperature-controlled Facilities To Accommodate Shipping Weight-loss Drugs

UPS has announced plans to put $48 cardinal successful temperature-controlled accommodation to support up pinch nan increasing request for weight-loss drugs.

One successful 8 adults successful nan U.S. has said they are taking a GLP-1 drug for weight nonaccomplishment aliases to dainty a chronic condition.

UPS wants to enactment up of orders for weight-loss narcotics and different medications by investing successful 27 accommodation that tin support GLP-1 narcotics astatine their required temperatures.

“These sites are designed to move delicate healthcare shipments quickly betwixt aerial and crushed while maintaining strict somesthesia ranges, helping trim consequence and guarantee medicines for illustration biologics, vaccines and different treatments get safely and fresh for diligent use,” UPS spokesperson Michelle Polk told The Independent.

“Think GLP-1 roar aliases highly targeted crab treatments that must stay wrong a precise [temperature] zone,” Polk said. “If they spell retired of nan zone, they can’t beryllium used…slowing down curen plans.”

The temperature-controlled facilities, which were first reported connected by CNBC, will beryllium located successful nan Americas, Europe and Asia.

A poll released by wellness argumentation statement KFF past November recovered that astir 12 percent of Americans said they are presently taking a GLP-1 supplier for illustration Ozempic and Wegovy. And astir 18 percent of respondents said they person taken nan medicine astatine immoderate point.

UPS isn’t nan only institution that is responding to nan surge successful request for weight-loss drugs.

When nan plus-size men’s clothing concatenation Destination XL saw sales autumn by astir 6 percent in nan 4th fourth of past fiscal year, nan institution partially blamed GLP-1 drugs.

“We didn't deliberation it was going to beryllium impacting nan business arsenic overmuch astatine nan level we deliberation coming it is,” DXL CEO Harvey Kanter said successful a telephone pinch analysts successful March.

Fast nutrient companies are besides adapting to nan changing appetites of their customers utilizing GLP-1 drugs

“While accelerated nutrient is not going away—convenience and affordability stay profoundly embedded successful U.S. culture—the scenery is shifting toward much intentional, health-aligned offerings,” dietician and glucosuria pedagogue Whitney Stuart told The Independent in February.

“We are already seeing fast-casual and accelerated nutrient brands accommodate by emphasizing smaller portions, protein-forward options, and nutrient density.”

UPS CEO Carol Tomé mentioned nan company’s activity successful nan healthcare sector, specifically its efforts to present temperature-sensitive medications, successful April.

“We've built a world-class end-to-end logistics web to grip nan astir analyzable clip and temperature-sensitive healthcare products, and these capabilities are enabling america to win,” Tomé said successful a first-quarter net call, according to Yahoo Finance.

“In nan first 4th of this year, we generated our first $3 cardinal healthcare gross 4th ever, pinch each 3 of our segments delivering year-over-year gross growth,” nan CEO added.

The world manufacture for nan proscription and retention of temperature-sensitive biologics — medications made from surviving organisms — was worthy $19.7 cardinal successful 2024, according to Growth Market Reports.

The marketplace is expected to grow astatine a compound yearly maturation complaint of 8.3 percent from 2025 to 2033, reaching an estimated $39.1 billion, nan marketplace investigation patient has said.

UPS spokesperson Polk said nan caller temperature-controlled accommodation bespeak “growing request for complete concatenation of custody, temperature-sensitive medicines and nan request for much precise, resilient cold-chain infrastructure worldwide.”